These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Exempt, with results 2009-016240-40 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE WITH THE REFERENCE PRODUCT CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE THERAPY WITH THE COMBINATION OF BENZOYL PEROXIDE-ERYTHROMYCIN/VE... not-yet-due
Exempt, with results 2009-016241-25 MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARATIVE WITH THE REFERENCE PRODUCT CLINICAL STUDY TO DEMONSTRATE THE SAFETY AND EFFICACY OF THE THERAPY WITH THE COMBINATION ERYTHROMYCIN-ISOTRETINOIN/VERISF... 2012-10-29 not-yet-due
Exempt, with results 2009-017201-11 MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARATIVE STUDY WITH THE REFERENCE PRODUCTS, FOR ASSESSMENT OF THERAPEUTIC SUPERIORITY OF THE COMBINATION CLINDAMYCIN-TRETINOIN/VERISFIELD, GEL, (1.0+0.025)%, (... 2011-11-14 not-yet-due
Reported results Terminated 2011-002386-38 Μονοκεντρική, τυχαιοποιημένη, διπλή-τυφλή, συγκριτική με πρωτότυπο φάρμακο κλινική μελέτη για την αξιολόγηση της αποτελεσματικότητας και της ασφάλειας της θεραπείας με Clindamycin vaginal suppositorie... 2015-10-19 due-trials
Reported results 2012-004993-25 A multicenter, randomized, patient-blind, investigator-blind, placebo-controlled, crossover study of Lidocaine + Prilocaine/Verisfield (2.5+2.5)% w/w cream and EMLA/AstraZeneca cream, in patients unde... 2013-07-04 due-trials
Reported results 2016-004292-41 Therapeutic Equivalence (non-inferiority), Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a Generic Formulation of Vaginal Ovule containi... 2018-04-30 due-trials
Other 2022-003070-23 A multicenter, randomized, double-blind, parallel, three-arm, active- and placebo-controlled therapeutic equivalence for the comparison of clindamycin + tretinoin/Verisfield gel (1+0.025)% with Acnata... not-yet-due